A phase 1/2 trial of ORIN1001, a first-in-class IRE1 inhibitor, in patients with advanced solid tumors.Nashat Y. Gabrail,Erika P. Hamilton,Anthony D. Elias,Mothaffar F. Rimawi,Chao Li, Maria Margarita Corvez,Wei Li, Ying Feng,Jiao Wei,Stephanie Greene, John Patterson, Qingping Zeng,Ai-Min HuiJOURNAL OF CLINICAL ONCOLOGY(2021)引用 9|浏览7暂无评分AI 理解论文溯源树样例生成溯源树,研究论文发展脉络Chat Paper正在生成论文摘要